A healthy start to 2025; guidance unchanged
30/04/25 -"Q1 results were ahead of expectations, driven by healthy growth in HIV, respiratory, immunology, and cancer medicines, offsetting a weaker showing from vaccines. Still, the management retained its ..."
Pages
71
Language
English
Published on
30/04/25
You may also be interested by these reports :
30/04/25
Q1 results were ahead of expectations, driven by healthy growth in HIV, respiratory, immunology, and cancer medicines, offsetting a weaker showing ...
30/04/25
Q1 sales slightly exceeded expectations. While the growth was largely driven by Biosimilars (similar to previous quarters), it was somewhat ...
29/04/25
Q1 profits exceeded the street’s expectations, supported by a healthy performance across segments. However, the management maintained its full-year ...
29/04/25
Q1 results exceeded consensus, aided by strong performances across focus areas. Consequently, the management raised its full-year outlook. While the ...